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requiring DAPT interruption, frequently recommended by non-cardiologists and most
commonly due to minor surgery.
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Background: Prasugrel demonstrated superior efﬁcacy in the reductionof events of acute
coronary syndrome (ACS), clopidogrel-naïve, patients treated with percutaneous coro-
nary intervention (PCI), especially in the diabetic (DM) subgroup. The objective of this
study is to assess the efﬁcacy and safety of switching from dual antiplatelet treatment with
clopidogrel to prasugrel inACSDMpatients being treatedwith everolimus-eluting stents.
Methods: Prospective, observational study conducted in 4 different centers. Patients
were included if they met the ADA criteria for established or increased risk for DM.
Platelet reactivity was measured before PCI and 1 month after with 2 different ana-
lyzers (VerifyNow P2Y12 test and Multiplate ADP-HS test); high on-treatment
platelet reactivity (HTPR) was deﬁned as any of the previously demonstrated values:
VerifyNow PRU >208, inhibition of platelet aggregation (IPA) < 20% or Multiplate
AUC>31. The presence of any complication, especially bleeding events, was recor-
ded both before discharge and at 1-month follow-up.
Results: Ninety-six patients were included: 638 years mean age, 77% male, 72%
hypertensive, 66% hyperlipidemic, 32% smokers (plus 23% ex-smokers), 80% ACS
with positive biomarkers, 58% multivessel disease. Only 16% of patients received
insulin. 15% of patients were diagnosed with diabetes and 21% with increased risk for
DM in the index admission. 10% of patients were previously treated with prasugrel
and 5% were changed back to clopidogrel by their treating physicians. Before the PCI,
71 patients (74%) showed HTPR (67% met the VerifyNow criteria, 37% according to
Multiplate results). At 1 month only 14% of patients showed HTPR; 3 of the 4 patients
on clopidogrel treatment (75%) still showed HTPR. After 1 month follow-up only 5
bleeding events were recorded: one caused by coronary perforation after PCI, one
signiﬁcant groin hematoma, 3 minor bleedings (epistaxis, skin hematomas), without
need of subsequent changes in treatment.
Conclusions: Switching from clopidogrel to prasugrel after stent treatment in ACS
diabetic patients is associated with a signiﬁcant reduction in platelet reactivity without
a relevant increase in bleeding complications.
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Background: CYP2C19 gene polymorphisms affect clopidogrel metabolism resulting
in variability in response. We sought to assess the frequency of CYP2C19 variants andB148 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstraassociation of stent thrombosis (ST) in a series of individuals undergoing percuta-
neous coronary intervention (PCI).
Methods: A case-control study of 10 patients with stent thrombosis and 38 patients
were routinely tested for CYP2C19 gene variants using the Verigene (Nanosphere Inc,
Illinois) and iPLEX assays (Sequenom Inc, San Diego). Patients were genotyped for
three single-nucleotide polymorphisms of the CYP2C19 alleles (*2, *3, *17).
Results: Of 48 patients undergoing gene testing 31(65%, 95%CI: 49%, 78%) carried a
loss-of-function (LOF) CYP2C19 allele. Call rate and concordance was 100% be-
tween the two assays. PCI was performed for acute coronary syndrome in 73% of
patients. In patients with a variant allele, 17(55%) were *2, 11 (35%) were *17, and
3(10%) were both *2 and *17. No patient had the CYP2C19*3 variant. LOF alleles
were present in 80% of patients with ST compared to 61% in patients without ST
(OR¼2.6, 95%CI: 0.5,14). Five patients with a LOF allele, had either a clopidogrel
dose increase or were changed to prasugrel, with no in-stent thrombosis in these
patients.
Conclusions: Carriage of a LOF CYP2C19 allele is associated with a higher odds
ratio of in-stent thrombosis in patients on standard dose clopidogrel, highlighting the
need for routine gene testing. Patients with a LOF allele should have alteration of
P2Y12 inhibitor therapy with either a higher dose of clopidogrel or a switch to pra-
sugrel or ticagrelor.
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Background: The aim of this analysis is to evaluate the bleeding risks of new oral
antiplatelet agents in real life.
Methods: All patients with ACS who underwent PCI during admission from September
2011 to December 2013 were included. Baseline characteristics and follow up were
collected prospectively. Bleeding risk was stratiﬁed according to PLATO deﬁnition.
Results: 869 patients were included with a mean age of 62,7 (SD 10,8). Most were
male (81%). Clinical admission: 40% were NSTEMI, 29,3% STEMI and 30,7% un-
stable angina. Median TIMI score was 3 pts, median GRACE score 124 pts and
median CRUSADE 25,7 pts. Clopidogrel was received 54,5%, prasugrel 32,7% and
ticagrelor 12,8%. CRUSADE score was lower in the prasugrel(p< 0,001) and tica-
grelor (p¼0,04)compared with clopidogrel. After a median follow up of 271 days, 92
(11,6%) bleeding events were detected:6,6% minor bleeding,4% mayor bleeding and
1,6% life threatening bleeding. On multivariate analysis STEMI (HR 2,25; CI95%
1,35-3,75;p¼0,002),prasugrel (HR 2,31;CI95% 1,43-1,72; p¼0,001), age (HR
1,036;CI95% 1,010-1,063;p¼0,006) and reduced creatinine clearance (HR 1,74;
CI95% 1,03-2,85;p¼0,037) predicted bleeding events. After analyzing only mayor
and life threatening events, prasugrel was not signiﬁcantly associated with mayor
bleeding events (HR 1,84; CI95% 0,89-3,80; p¼0,097).cts/Pharmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: Prasugrel was associated with an increased risk of total bleeding;
however it was not signiﬁcantly associated with mayor and life threatening bleeding
events. Ticagrelor was not signiﬁcantly associated with any king of bleeding
compared to clopidogrel.
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Background: Although dual antiplatelet therapy (DAPT) is commonly prescribed
after lower extremity peripheral artery interventions, its optimal duration has not yet
been established.
Methods: We analyzed 494 limb interventions from 367 patients between July 2005
and May 2014 enrolled in the multicenter Excellence in Peripheral Artery Disease
(XLPAD) registry (NCT01904851) for the primary endpoint (death, myocardial
infarction, coronary or limb revascularization, unplanned amputation and surgical
revascularization) over a 12 month period based on the duration of prescribed or
received DAPT.
Results: DAPT was prescribed following 92.3% procedures, with 228 (50%) each in
3 months and >3 months duration. After adjusting for ankle brachial index,
Rutherford category, and cardiovascular risk factors, primary endpoint free survival
was similar between prescription groups (hazard ratio [HR]: 0.99, 95% conﬁdence
interval [CI]: 0.55-1.78; p¼0.998). 50.9% actually received 3 months DAPT while
49.1% received >3 months, with no differences in primary endpoint free survival
(HR: 1.16, 95% CI: 0.69-1.95; p¼0.567). Importantly, >3 DAPT duration was more
often prescribed to patients with prior coronary artery disease (p< 0.001, Figure 1).Conclusions: Experience across operators suggests equipoise in the selection of
DAPT duration after peripheral artery intervention, with longer prescription duration
selected for patients with preexisting coronary artery disease.
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Background: Recent trials indicate that both Ticagrelor and Prasugrel are superior to
Clopidogrel in preventing cardiovascular events. However, as to date, no trials have
been conducted comparing these drugs directly. We compared 30-day mortality in
patients with STEMI receiving Ticagrelor or Prasugrel.
Methods: This retrospective study included 1069 consecutive STEMI-patients in the
Catharina Hospital, Eindhoven area, The Netherlands. From April 2012 until April
2013, patients received Prasugrel loading (60mg) and maintenance dose (patients
older than 75 years or weighing less than 60 kg were given Clopidogrel). From April
2013 onward, they received Ticagrelor loading (180mg) and maintenance dose. Death
was deﬁned as death from any cause within 30 days after primary PCI. Binary logistic
regression was used for comparison of anti-platelet strategies.
Results: No patients were lost to follow-up. In the Ticagrelor group 28 out of 524
patients (5.3%) died within 30 days after PCI, as compared to 21 out of 545 patients
(3.9%) in the ’Prasugrel/Clopidogrel’ group (OR, 1.4;95% CI, 0.79 to 2.5; p¼0.2).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ReAnalysis of the Ticagrelor group compared with Prasugrel alone ((n¼305) by
excluding Clopidogrel-treated patients) showed a 2.3% mortality in the Prasugrel
group (OR, 2.4;95% CI, 1.04 to 5.57; p¼0.04). However, after adjusting for age, no
signiﬁcant difference was found between Ticagrelor and Prasugrel treated patients
(OR, 1.5; 95% CI 0.61 to 3.6; p¼0.4).Conclusions: We found no signiﬁcant difference in 30-day mortality in STEMI-
patients treated with Ticagrelor or Prasugrel in a large, retrospective, single-centre
study.Renal and Mesenteric Intervention
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Background: Renal Artery Aneurysms (RAAs) can be surgically treated but due to
high risk, endovascular procedures have been proposed (coils, graft...). All these
techniques have some drawbacks, potential complications and contraindications. We
propose a new technique: the Multilayer Flow Modulator (MFM*), a self expandable.
Methods: This MFM* is a 3D braided tube made of several interconnected layers
without any covering. Our earliest tests, in vitro (theorical simulation computerized
Fluid dynamics, Molecular Modelization) & in vivo. demonstrate that this MFM*
reduces the velocity in the aneurismal sac up to 90% by modifying the hemodynamic
conditions.. A saccular aneurysm (A.) without collateral branch will thrombose
quickly. If a collateral branch is present the ﬂow is directed towards this branch
leading to shrinkage of the aneurysm. In fusiform A. the ﬂow is laminated, the vor-
texes eliminated, eliminating the risk of rupture. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this MFM preserves
the collateral branches and increases the ﬂow in them, allowing the possibility to cover
any artery without compromising the ﬂow.
Results: 8 RAAs (right:5, left: 3) in 8 pts (male: 3) mean age 58 y. treated with MFM*
6 pts had atheromatous disease, 2 a ﬁbromuscular dysplasia. One pt had a solitary
kidney. All these pts had hypertension. 10 MFM*(⌀: 5 to 6 mm, length 30 to 60 mm)
loaded in a 6 F sheath implanted by femoral approach through 8 F guiding catheter.
These stents covered major renal branches without compromising the ﬂow. Technical
success: 100%. No complications. Immediately: important reduction of the velocities
inside the aneurismal sac. 6 to 36 month follow up will be presented. All aneurysms
thrombosed with diameter reduction in some pts. The thrombosis could take several
weeks depending on the importance of collateral branches. All the side branches
remain patent.nal and Mesenteric Intervention B149
